Login
← Go Back
Cohance Lifesciences
COHANCE · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti · MD: Venkateswarlu Jasti · Listing date: March 10, 2020 · Employees: 1114 · Hyderabad · http://www.suvenpharm.com
Stock Price vs Company Growth
1d
0.9%
1w
3.6%
1m
26.7%
3m
41.1%
6m
48.4%
1y
58.0%
5y
7.7%
all
23.2%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 544 0.9%
534
1,038
Company Overview
Sales
1,814 Cr
Growth: 25.6%
Profit after Tax
248 Cr
Growth: -20.6%
Mid Cap
20,812 Cr
P/E: 67.4x
Industry P/E: 33.3x
Fundamentals
Sales (Cr) ₹ 1,814
Growth 25.6%
EBITDA 23.4%
P/S 11.4x
Dividend 0.0%
P/E 67.4x
Book Value ₹ 47.9
PEG Ratio 2.7x
ROE 13.0%
P/B 11.4x
Shareholding Pattern
Institutions
Uti Small Cap Fund
2.17 %
L And T Mutual Fund Trustee Ltd-L And T Mid Cap Fund
1.95 %
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Others
Rambabu Chirumamilla
2.14 %
Qualified Institutional Buyer
0.7 %
Iepf
0.14 %
Increase    Decrease    No change
Company Profile Detailed
The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc.
Belongs to (27 Indices) view more
Investors (33)
landt.mu...
marshall...
rajarshi...
Followers (4)
ramakris...
krishna5...
venkatja...